- 1、本文档共59页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
早期乳腺癌助化疗进展 中国医学科学院肿瘤医院 徐兵河
早期乳腺癌辅助化疗进展 中国医学科学院肿瘤医院 徐兵河 中国乳腺癌发病概况 每年约有19万新发乳腺癌病例 2002年全国乳腺癌年龄标化发病率:18.7/100,000;死亡率: 5.5/100,000 发病率:城市>农村 高发年龄段:45-50岁 近15年来乳腺癌发病率上升死亡率下降 死亡率下降的原因 The benefits of chemotherapy data from clinical trails Early Breast Cancer Trialists Collaborative Group (EBCTCG). 194 randomised trials of adjuvant chemotherapy (CMF,CAF,CEF) or hormonal therapy (TAM) that began by 1995. 15-year probabilities of recurrence in women aged 50 years, with / without polychemotherapy 15-year probabilities of breast cancer mortality in women aged 50 years, with / without polychemotherapy 15-year probabilities of recurrence in women aged 50-69 years, with / without polychemotherapy 15-year probabilities of breast cancer mortality in women aged 50-69 years, with / without polychemotherapy 15-year probabilities of recurrence in women with ER+ (or ER-unknown) disease, with / without ~5 years tamoxifen 15-year probabilities of breast cancer mortality in women with ER+ (or ER-unknown) disease, with / without ~5 years tamoxifen 5-year recurrence in women with ER+ (or ER-unknown) disease with no chemotherapy, with / without ~5 years tamoxifen 5-year recurrence in women with ER+ (or ER-unknown) disease with chemotherapy, with / without ~5 years tamoxifen Chemotherapy versus endocrine therapy in the treatment of breast cancer In premenopausal women, polychemotherapy improves 15-year recurrence by 12.4% and survival by 10.0% In postmenopausal women, 15-year gains in recurrence and survival are smaller (4.2% and 3.0%, respectively) anthracycline-based polychemotherapy reduces the annual death rate by 38% for women <50 years and by 20% for those of age 50-69 years Chemotherapy versus endocrine therapy in the treatment of breast cancer In patients with ER+ disease, tamoxifen improves 15-year recurrence by 11.8% and survival by 9.2% Gains made with tamoxifen treatment appear to be irrespective of adjuvant chemotherapy 乳腺癌辅助化疗进展 Five Year follow-up of INT C9741: Dose-dense chemotherap
您可能关注的文档
- 新生儿呼吸机应用6月.ppt
- 新生儿室医院感染制制度与措施.ppt
- 新生儿呼机应用及护理对.ppt
- 新生儿早期症状别 王莉_图文.ppt
- 新生儿机械气相关性肺炎.ppt
- 新版《煤矿安规程》考试题库及答案.ppt
- 新生儿专业护理 精品培训教学课件图文.ppt.ppt
- 新生儿病房防院内感染措施1.ppt.ppt
- 新生儿科护理记录及填写说明方案.ppt
- 新版人教版小学英语五年级册unit3 b let’s talk讲解材料.ppt
- 期末复习课件++专题7+阿基米德原理++2023-2024学年人教版八年级物理下册.pptx
- 4-1电磁振荡(教学课件)高中物理人教版选择性必修第二册.pptx
- 本包含页空白页.pdf
- 【会计实操经验】财务操纵的知识框架.pdf
- 英国b2c电商网站ocado市场前景及投资研究报告-培训课件外文版2024.6,拼多多,阿里巴巴,1688,temu,tiktok.pdf
- 印尼在线约会行业市场前景及投资研究报告-培训课件外文版2024.6,微信,tiktok.pdf
- 印尼物联网IOT行业市场前景及投资研究报告-培训课件外文版2024.5.pdf
- 印尼斋月消费情况分析报告-培训课件外文版2024.6.pdf
- 英国GDP分析报告-培训课件外文版2024.6.pdf
- 印尼铁路行业市场前景及投资研究报告-培训课件外文版2024.6,援建高铁.pdf
文档评论(0)